Description:
This is a Phase 2/3, randomized, open-label study for the treatment of patients with
HER2-positive Gastric cancer (GC) or Gastroesophageal Junction (GEJ) cancer to determine the
efficacy of margetuximab combined with INCMGA00012 (also known as MGA012) (Cohort A) and
margetuximab combined with INCMGA00012 or MGD013 and chemotherapy compared to trastuzumab
combined with chemotherapy (Cohort B).
Title
- Brief Title: Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY)
- Official Title: Phase 2/3 Trial to Evaluate Margetuximab in Combination With INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer
Clinical Trial IDs
- ORG STUDY ID:
CP-MGAH22-06
- NCT ID:
NCT04082364
Conditions
- Gastric Cancer
- Gastroesophageal Junction Cancer
- HER2-positive Gastric Cancer
Purpose
This is a Phase 2/3, randomized, open-label study for the treatment of patients with
HER2-positive Gastric cancer (GC) or Gastroesophageal Junction (GEJ) cancer to determine the
efficacy of margetuximab combined with INCMGA00012 (also known as MGA012) (Cohort A) and
margetuximab combined with INCMGA00012 or MGD013 and chemotherapy compared to trastuzumab
combined with chemotherapy (Cohort B).
Detailed Description
A single-arm cohort (Cohort A, 40 to 110 patients) will evaluate safety and efficacy of
margetuximab plus INCMGA00012. In a 4-arm cohort (Cohort B Part 1, 50 patients per arm),
patients will be randomized to margetuximab plus chemotherapy plus INCMGA00012, margetuximab
plus chemotherapy plus MGD013, margetuximab plus chemotherapy, or trastuzumab plus
chemotherapy. A checkpoint inhibitor (CPI) (INCMGA00012 or MGD013) will be selected from
Cohort B Part 1 and evaluated in a randomized 2-arm cohort (Cohort B Part 2, 250 patients per
arm) of margetuximab plus chemotherapy plus INCMGA00012 or MGD013, or trastuzumab plus
chemotherapy.
Trial Arms
Name | Type | Description | Interventions |
---|
Margetuximab plus INCMGA00012 | Experimental | margetuximab plus INCMGA00012 | |
Margetuximab plus INCMGA00012 plus chemo | Experimental | margetuximab plus INCMGA00012 plus capecitabine and oxaliplatin (XELOX) or modified 5-FU, leucovorin, and oxaliplatin regimen 6 (mFOLFOX-6) | |
Margetuximab plus MGD013 plus chemo | Experimental | margetuximab plus MGD013 plus XELOX or mFOLFOX-6 | |
Margetuximab plus chemo | Experimental | margetuximab plus XELOX or mFOLFOX-6 | |
Control Arm | Active Comparator | Trastuzumab plus XELOX or mFOLFOX-6 | |
Eligibility Criteria
Key Inclusion Criteria:
- Histologically confirmed diagnosis of previously untreated locally advanced
unresectable or metastatic HER2+ GC or GEJ adenocarcinoma
1. Prior systemic perioperative treatment is allowed; however the patient must have
had a disease-free interval of at least 6 months from end of chemo/surgery
2. Patients receiving perioperative anti-HER2 therapy require testing of HER2 status
for eligibility
3. Cohort A: HER2-positive (by IHC 3+) and PD-L1-positive (by IHC with 22C3 CPS ≥
1%) per central review
4. Cohort B: HER2-positive (by IHC 3+ or IHC 2+ in combination with FISH+) by local
review. PD -L1 status is not required for enrollment.
- Availability of formalin-fixed, paraffin-embedded tumor specimen, unstained slides or
contemporaneous biopsy for tumor target testing
- Eastern Cooperative Oncology Group performance status of 0 or 1, verified within 3
days of Day 1
- Life expectancy ≥ 6 months
- At least one radiographically measurable target lesion
- Acceptable laboratory parameters and adequate organ function
Key Exclusion Criteria:
- Other malignancy that is progressing or required treatment within the past 5 years,
with certain exceptions
- Patients with known MSI-H status
- History of allogeneic stem cell or tissue/solid organ transplant
- Central nervous system metastases
- Clinically significant cardiovascular disease, gastrointestinal disorders, pulmonary
compromise
- Prior neoadjuvant or adjuvant treatment with immunotherapy
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Incidence of Adverse Events of margetuximab plus INCMGA00012 as assessed by CTCAE v5.0 |
Time Frame: | 6 month intervals |
Safety Issue: | |
Description: | Evaluation of adverse events and serious adverse events (Cohort A) |
Secondary Outcome Measures
Measure: | Progression-free survival |
Time Frame: | Up to 3 years |
Safety Issue: | |
Description: | Time from start of study treatment to the first documented disease progression per RECIST v1.1 or death due to any cause, whichever occurs first. (Cohorts A and B) |
Measure: | Duration of response |
Time Frame: | Up to 3 years |
Safety Issue: | |
Description: | Time from the date of initial response (CR or PR) to the date of first documented progression or death from any cause, whichever occurs first (Cohorts A and B) |
Measure: | Disease control rate |
Time Frame: | Up to 3 years |
Safety Issue: | |
Description: | Percentage of patients who experienced response of CR, PR or stable disease for at least 3 months from start of study treatment (Cohorts A and B) |
Measure: | Patient reported quality of life |
Time Frame: | Up to 3 years |
Safety Issue: | |
Description: | Quality of life as assessed using the Functional Assessment of Cancer Therapy - Gastric Questionnaire (FACT-Ga) (Cohort B) on a scale of 0 to 184. Lower scores correlate with worse quality of life and higher scores correlate with better quality of life. |
Details
Phase: | Phase 2/Phase 3 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | MacroGenics |
Trial Keywords
- gastric cancer
- gastroesophageal junction cancer
- HER2-positive gastroesophageal cancer
- anti-HER2 therapy
- checkpoint inhibitors
- PD-1
- LAG-3
Last Updated
May 3, 2021